Last edition
News about "metastatic prostate cancer treatment"
EMA Validates Hengrui Pharma's Fuzuloparib MAA
Hengrui Pharma has announced EMA validation of MAA for Wevdury (fuzuloparib) in combination with abiraterone for metastatic castration-resistant prostate cancer.
Metastatic Prostate Cancer Treatment | 12/10/2026 | By News Bureau
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy
pharmaindustrial-india.com - Professional magazine for pharma industry suppliers and lab technology - CEDRO members